Bölüm notları
It's an unusually rich week for acromegaly research — five new papers spanning a first-in-human antagonist trial and two large Swedish outcomes studies — while the rare disease industry saw a $1.3B rare-epilepsy buyout, a bankruptcy-auction gene therapy pickup, and a safety scare over a newly approved Prader-Willi drug.

